Symbols

SVRA

Savara

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 1

Bearish Engulfing

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SVRA

Savara Inc.

A biopharmaceutical company that develops and commercializes therapies for rare respiratory diseases

Industry

Biological Technology

Established Date

Invalid Date

Listing Date

04/28/2017

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.savarapharma.com;www.masttherapeutics.com

Security Type

Common stock

Office address

1717 Langhorne Newtown Road, Suite 300 Langhorne, Pennsylvania 19047

Business

Introduction

Savara Inc., a Delaware corporation, is a biopharmaceutical company engaged in the development of treatments for serious or life-threatening diseases. The Company has been dedicating the vast majority of its resources to research and development (" R&D ") and the acquisition of its product candidates. The company has not yet listed or sold any products or generated any significant revenue. In 2011, through the Company's acquisition of SynthRx Co., Ltd., the Company acquired the Company's membrane adhesion and sealant technology platform, which includes proprietary poloxam-related data and developed knowledge with more than 20 years of clinical, non-clinical and manufacturing experience, and the Company is utilizing the MST -188 developed by the Master platform to treat diseases characterized by microcirculatory insufficiency conditions. In previous years, the company was developing Exelbine and ANX-514, both of which are investigational oncology programs, but at the beginning of 2012, the company has focused its resources almost entirely on the development of MST-188. The company was incorporated in Delaware in December 1995.

Company Financials

EPS

SVRA has released its 2025 Q1 earnings. EPS was reported at -0.12, versus the expected -0.13, beating expectations. The chart below visualizes how SVRA has performed over recent quarters, highlighting trends in earnings surprises.